Protein binding of tolfenamic acid in the plasma from patients with renal and hepatic disease
- PMID: 3758148
- DOI: 10.1007/BF00542420
Protein binding of tolfenamic acid in the plasma from patients with renal and hepatic disease
Abstract
The protein binding of tolfenamic acid in plasma from patients with renal and hepatic disorders was studied by equilibrium dialysis. Drug binding to the cellular components of whole blood and blood cell suspensions was also measured. Salicylic acid was used as the reference drug in all experiments. Renal and hepatic diseases increased the unbound fraction of tolfenamic acid. Free drug fractions were significantly correlated with changes in creatinine, urea, and total bilirubin, but not with those in albumin or total protein in plasma. Comparison of the theoretical binding parameters in control plasma and similar changes in protein binding in all the plasma samples studied revealed that tolfenamic acid and salicylic acid probably share a common primary binding site. The significance of the correlation permits use of salicylic acid as a model drug for predicting changes in the protein binding of tolfenamic acid. The measurements of binding properties in whole blood and blood cell--buffer suspension showed that tolfenamic acid interacts with the lipid membrane structures of blood cells, while salicylic acid is distributed into the aqueous cell space.
Similar articles
-
The effect of ageing on plasma albumin and plasma protein binding of diazepam, salicylic acid and digitoxin in healthy subjects and patients with renal impairment.Br J Clin Pharmacol. 1992 Mar;33(3):299-304. doi: 10.1111/j.1365-2125.1992.tb04039.x. Br J Clin Pharmacol. 1992. PMID: 1576051 Free PMC article.
-
Tolfenamic acid is a potent CYP1A2 inhibitor in vitro but does not interact in vivo: correction for protein binding is needed for data interpretation.Eur J Clin Pharmacol. 2007 Sep;63(9):829-36. doi: 10.1007/s00228-007-0335-z. Epub 2007 Jul 6. Eur J Clin Pharmacol. 2007. PMID: 17618427 Clinical Trial.
-
Blood binding of selezen (imidazole salicylate) in man.Int J Clin Pharmacol Ther Toxicol. 1991 Jun;29(6):242-9. Int J Clin Pharmacol Ther Toxicol. 1991. PMID: 1869346
-
Clinical pharmacokinetics of the salicylates.Clin Pharmacokinet. 1985 Mar-Apr;10(2):164-77. doi: 10.2165/00003088-198510020-00004. Clin Pharmacokinet. 1985. PMID: 3888490 Review.
-
Chemopreventive Properties of Tolfenamic Acid: A Mechanistic Review.Curr Med Chem. 2018;25(14):1598-1608. doi: 10.2174/0929867324666170414155107. Curr Med Chem. 2018. PMID: 28413959 Review.
Cited by
-
Distribution and elimination characteristics of 111In-DTPA-D-phe1-octreotide and 111In-DTPA-L-phe1-octreotide in rats.Eur J Drug Metab Pharmacokinet. 2002 Jan-Mar;27(1):37-43. doi: 10.1007/BF03190403. Eur J Drug Metab Pharmacokinet. 2002. PMID: 11996325
-
Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).Clin Pharmacokinet. 1990 Sep;19(3):218-29. doi: 10.2165/00003088-199019030-00005. Clin Pharmacokinet. 1990. PMID: 2203581 Review.
-
Kidney and liver contributions to salicylate metabolism in rats.Eur J Drug Metab Pharmacokinet. 1994 Jan-Mar;19(1):21-6. doi: 10.1007/BF03188818. Eur J Drug Metab Pharmacokinet. 1994. PMID: 7957447
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical